IP Library Granted Patent US 11,998,555
Granted Patent B2
US 11,998,555 · App. 17/426,765 · Granted Jun 4, 2024

Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Inventors: Alfredo Grossi (Stoneham, MA); Britt Kostraba (Sandown, NH); Olatokumbo O. Luca Ogunleye (Tewksbury, MA); Shannon Terry (Somerville, MA); Franciscus Koppenhagen (Salem, NH)
Assignee: scPharmaceuticals Inc.
A61K31/635A61K47/10A61K47/18A61K47/32A61M5/14248
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,998,555
App. No.
17/426,765
Granted
Jun 4, 2024
Kind
B2
Abstract

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Claims (32)

1. A liquid pharmaceutical formulation comprising:

(i) furosemide, or a pharmaceutically acceptable salt thereof;

(ii) benzyl alcohol, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.1% (w/w) to about 10% (w/w); and

(iii) a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 25 mM to about 100 mM,

wherein the concentration of furosemide in the liquid pharmaceutical formulation is greater than about 40 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5.

2. The liquid pharmaceutical formulation of claim 1 , wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w).

3. A liquid pharmaceutical formulation, comprising:

(i) furosemide, or a pharmaceutically acceptable salt thereof;

(ii) from about 0.1% (w/w) to about 10% (w/w) benzyl alcohol; and

(iii) from about 25 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof,

wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL.

4. The liquid pharmaceutical formulation of claim 3 , wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w).

5. The liquid pharmaceutical formulation of claim 3 , wherein the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5.

6. The liquid pharmaceutical formulation of claim 3 , wherein the pH of the liquid pharmaceutical formulation is from about 7.0 to about 8.0.

7. A unit liquid pharmaceutical formulation comprising:

(i) from about 10 mg to about 200 mg furosemide, or a pharmaceutically acceptable salt thereof;

(ii) from about 0.1% (w/w) to about 10% (w/w) benzyl alcohol; and

(iii) from about 25 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof,

wherein the concentration of furosemide in the unit liquid pharmaceutical formulation is from about 40 mg/mL to about 200 mg/mL and the pH of the unit liquid pharmaceutical formulation is from about 6.5 to about 8.5.

8. The unit liquid pharmaceutical formulation of claim 7 , wherein the amount of benzyl alcohol in the unit liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w).

9. The liquid pharmaceutical formulation of claim 1 , further comprising one of more of water; a pH adjuster; and an osmolarity adjuster.

10. The liquid pharmaceutical formulation of claim 9 , wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof.

11. A method of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of claim 1 .

12. The method of claim 11 , wherein the liquid pharmaceutical formulation is administered to the patient by subcutaneous injection or subcutaneous infusion.

13. The method of claim 12 , wherein the liquid pharmaceutical formulation is administered to the patient by subcutaneous infusion using an on-body, subcutaneous delivery system.

14. A kit for the treatment of congestion, edema, fluid overload, or hypertension comprising the unit liquid pharmaceutical formulation of claim 7 .

15. The kit of claim 14 , comprising one, two, three or more units of the unit liquid pharmaceutical formulation.

16. The liquid pharmaceutical formulation of claim 3 , further comprising one of more of water; a pH adjuster; and an osmolarity adjuster.

17. The liquid pharmaceutical formulation or the unit liquid pharmaceutical formulation of claim 16 , wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof.

18. The unit liquid pharmaceutical formulation of claim 7 , further comprising one of more of water; a pH adjuster; and an osmolarity adjuster.

19. The unit liquid pharmaceutical formulation of claim 18 , wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof.

20. The unit liquid pharmaceutical formulation of claim 7 , wherein the pH of the unit liquid pharmaceutical formulation is from about 7.0 to about 8.0.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2026
From: SCPHARMACEUTICALS INC.
To: MANNKIND CORPORATION
Reel/Frame 075534/0309 →
PATENT SECURITY AGREEMENT Recorded Nov 11, 2025
From: SCPHARMACEUTICALS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 073569/0001 →
RELEASE OF SECURITY INTEREST Recorded Oct 8, 2025
From: PERCEPTIVE CREDIT HOLDINGS IV, LP
To: SCPHARMACEUTICALS INC.
Reel/Frame 072511/0726 →
SECURITY INTEREST Recorded Aug 13, 2024
From: SCPHARMACEUTICALS INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 068261/0702 →
RELEASE OF SECURITY INTEREST Recorded Aug 9, 2024
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: SCPHARMACEUTICALS INC.
Reel/Frame 068244/0093 →
SECURITY INTEREST Recorded Oct 13, 2022
From: SCPHARMACEUTICALS INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 061419/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: GROSSI, ALFREDO; KOSTRABA, BRITT; OGUNLEYE, OLATOKUMBO O. LUCA; TERRY, SHANNON; KOPPENHAGEN, FRANCISCUS
To: SCPHARMACEUTICALS INC.
Reel/Frame 061317/0727 →
Continuity (2)
Provisional Application 62799215 · Jan 31, 2019
Related Publication 20220096500A1 · Mar 31, 2022